Detalhe da pesquisa
1.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Lancet
; 403(10422): 147-159, 2024 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38008109
2.
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
J Allergy Clin Immunol
; 153(2): 479-486.e4, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37866460
3.
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
J Allergy Clin Immunol
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38431226
4.
Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial.
Allergy
; 79(1): 93-103, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597162
5.
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase 2b multinational, randomised, double-blind, placebo-controlled ARROYO trial.
Br J Dermatol
; 2024 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38367194
6.
Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes.
Acta Derm Venereol
; 104: adv25576, 2024 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38189220
7.
Differential diagnosis of contact dermatitis: A practical-approach review by the EADV Task Force on contact dermatitis.
J Eur Acad Dermatol Venereol
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713001
8.
Polysensitization in the Spanish Contact Dermatitis Registry (REIDAC): A 2019-2022 prospective study with cluster and network analysis.
J Eur Acad Dermatol Venereol
; 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38411353
9.
2-Hydroxyethyl methacrylate (2-HEMA) sensitization, a global epidemic at its peak in Spain?
Contact Dermatitis
; 90(5): 507-513, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38351475
10.
Sensitization to textile dyes in Spain: Epidemiological situation (2019-2022).
Contact Dermatitis
; 90(5): 486-494, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38348533
11.
Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study.
J Allergy Clin Immunol
; 152(5): 1095-1106, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37574079
12.
Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances.
Allergy
; 78(2): 389-401, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36448493
13.
Treatment patterns and outcomes in patients with chronic urticaria during pregnancy: Results of PREG-CU, a UCARE study.
J Eur Acad Dermatol Venereol
; 37(2): 356-364, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066999
14.
Which outcomes should be measured in hand eczema trials? Results from patient interviews and an expert survey.
J Eur Acad Dermatol Venereol
; 37(6): 1199-1206, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36695080
15.
Allergic reactivity for different dilutions of eugenol in repeated open application test and patch testing.
Contact Dermatitis
; 89(2): 95-102, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37218587
16.
The European baseline series and recommended additions: 2023.
Contact Dermatitis
; 88(2): 87-92, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36443008
17.
Occupational contact allergy: The European perspective-Analysis of patch test data from ESSCA between 2011 and 2020.
Contact Dermatitis
; 88(4): 263-274, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36694979
18.
Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019-2021 epidemiological situation.
Contact Dermatitis
; 88(3): 212-219, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36403138
19.
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.
J Allergy Clin Immunol
; 150(6): 1498-1506.e2, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36096203
20.
CRUSE - What the first 100 days have taught us.
Qatar Med J
; 2023(2): 14, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38025340